In addition to delayed larval development, the body weight of animals expressing Met^Scer\UAS.cBa driven by Scer\GAL4^Adh.PF in a hemizygous Met^W3 mutant background is dramatically reduced in comparison to Scer\GAL4^Adh.PF controls. Once these mutants reach wandering third instar larval stage, their fat body cells begin to dissociate and undergo dramatic apoptosis.

The Met^hs.PA transgenic line autonomously expressing Met^Scer\UAS.cBa shows higher susceptibility to methoprene than wild-type controls. The increased susceptibility is reflected by the survival values and by the increased fraction of adults from cultures exposed to lower sub-lethal dose that show methoprene-induced morphogenetic defects, such as sternite bristle defects or abnormally rotated male genitalia.

Embryonic development progresses normally in P{UAS-Met.B}pV2 transgenic animals expressing Met^Scer\UAS.cBa at high levels. Although post-embryonic development of these animals is somewhat delayed, survival rates are similar to that of wild-type controls.

Compared to controls, expression of Met^Scer\UAS.cBa increases the sensitivity of larvae to methoprene and alters the sensitive period.

Larvae expressing Scer\GAL4^tub-driven Met^Scer\UAS.cBa begin dying a day after hatching and rarely pupariate and survive to adulthood.

Survival to adulthood of larvae expressing Scer\GAL4^Act-driven Met^Scer\UAS.cBa is poor. However, the lethality of Met^Scer\UAS.cBa driven by Scer\GAL4^Act is much stronger in the highly-expressing P{UAS-Met.B}pV2 line, in which case no pupae are found.

Expression of Met^Scer\UAS.cBa (either autonomously or driven by Scer\GAL4^Act) appears to have no effect on oogenesis and oviposition.